Valuation: Crossject

Market Cap 7.13Cr 7.99Cr 6.64Cr 6.05Cr 11Cr 769.95Cr 11Cr 80Cr 31Cr 392.97Cr 30Cr 29Cr 1.26TCr P/E 2026 *
3.2x
P/E 2027 * 2.52x
Enterprise Value 5.34Cr 5.99Cr 4.98Cr 4.53Cr 8.53Cr 576.71Cr 8.59Cr 60Cr 23Cr 294.35Cr 22Cr 22Cr 946.13Cr EV / Sales 2026 *
0.88x
EV / Sales 2027 * 0.37x
Free-Float
92.46%
Yield 2026 *
-
Yield 2027 * -
Manager TitleAgeSince
Chief Executive Officer 63 08/08/2001
Director of Finance/CFO - 25/03/2026
Corporate Officer/Principal - 20/08/2024
Director TitleAgeSince
Chairman 67 26/06/2009
Director/Board Member 67 -
Director/Board Member - -
Change 5-day change 1-year change 3-year change Capi.($)
-17.93%-.--% - - 8.03Cr
+2.67%-1.17%-25.63%+4.65% 17TCr
+1.84%-0.76%-9.96%+15.34% 11TCr
+3.55%+4.72%-23.02%+7.15% 11TCr
+1.19%+0.42%-48.90%-11.41% 7.39TCr
+1.90%+2.61%+4.02%+72.41% 5.9TCr
+1.32%+4.32%+14.41%+64.37% 5.13TCr
+2.19%-1.71%-6.68%-30.44% 4.82TCr
+1.67%+1.50%-16.50%+21.67% 4.08TCr
+1.80%+0.32%+29.60%-0.91% 3.22TCr
Average -0.04%-0.86%-9.18%+15.87% 7.67TCr
Weighted average by Cap. +2.14%-1.30%-15.26%+13.55%

Financials

2026 *2027 *
Net sales 6.08Cr 6.82Cr 5.66Cr 5.15Cr 9.71Cr 656.37Cr 9.78Cr 68Cr 27Cr 335Cr 26Cr 25Cr 1.08TCr 6.52Cr 7.31Cr 6.07Cr 5.53Cr 10Cr 703.87Cr 10Cr 73Cr 29Cr 359.24Cr 27Cr 27Cr 1.15TCr
Net income 2.83Cr 3.17Cr 2.64Cr 2.4Cr 4.52Cr 305.51Cr 4.55Cr 32Cr 12Cr 155.93Cr 12Cr 12Cr 501.21Cr 3.56Cr 3.99Cr 3.32Cr 3.02Cr 5.68Cr 384.32Cr 5.73Cr 40Cr 16Cr 196.15Cr 15Cr 15Cr 630.5Cr
Net Debt -1.79Cr -2.01Cr -1.67Cr -1.52Cr -2.86Cr -193.24Cr -2.88Cr -20Cr -7.84Cr -99Cr -7.53Cr -7.37Cr -317.02Cr -4.7Cr -5.27Cr -4.38Cr -3.98Cr -7.5Cr -507.39Cr -7.56Cr -53Cr -21Cr -258.96Cr -20Cr -19Cr -832.4Cr
Logo Crossject
Crossject specializes in manufacturing and marketing needleless drug self-injection. The group provides Zeneo, a prefilled and single-use device that can be used for intradermal, subcutaneous and intramuscular injections.
Employees
99
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-